Metraipolis › archive › dc_9ae4df2ea92e

Evaluation of comorbidity burden on disease progression and mortality in patients with interstitial pneumonia with autoimmune features: A retrospective cohort… — Europe PMC PMID:39903746

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/39903746
DOI: 10.1371/journal.pone.0316762
License (as archived): CC0-1.0
Archived: 2026-10-06T13:45:18.549Z
SHA-256 of the archived text: ebb4f68c3e7cc48df474d65070a01645bdc3264a782be58e23520f06070a4330
Stable URL of this page: https://metraipolis.com/documento/dc_9ae4df2ea92e

How to cite

Evaluation of comorbidity burden on disease progression and mortality in patients with interstitial pneumonia with autoimmune features: A retrospective cohort… — Europe PMC PMID:39903746 — Europe PMC (en), https://europepmc.org/article/MED/39903746 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_9ae4df2ea92e (Metraipolis archive dc_9ae4df2ea92e, sha256 ebb4f68c3e7cc48df474d65070a01645bdc3264a782be58e23520f06070a4330)

BibTeX

@misc{dc9ae4df2ea92e,
  title = {Evaluation of comorbidity burden on disease progression and mortality in patients with interstitial pneumonia with autoimmune features: A retrospective cohort… — Europe PMC PMID:39903746},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/39903746},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_9ae4df2ea92e; sha256 ebb4f68c3e7cc48df474d65070a01645bdc3264a782be58e23520f06070a4330},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/39903746. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Background: Interstitial pneumonia with autoimmune features (IPAF) is a subset of interstitial lung disease that manifests with features of autoimmunity while not meeting classification criteria for a defined rheumatic disease. Comorbidity burden is an important prognostic indicator in various rheumatic and interstitial lung diseases, but few studies have commented on comorbidities in this population. This study was conducted to evaluate the association of individual comorbidities, the Charlson Comorbidity Index (CCI), and the Rheumatic Disease Comorbidity Index (RDCI) with lung disease progression and transplant/mortality outcomes in patients with IPAF. Methods: In a retrospective study, we evaluated the prevalence and severity of comorbidities in an institutional cohort of patients with IPAF. Using Cox regression, we correlated the association of individual comorbidities and comorbidity indices with time to lung disease progression (relative forced vital capacity decline of 10% or more) and with time to lung transplant/death. We compared the performance of CCI and RDCI in predicting outcomes. Results: History of cerebrovascular accident (CVA) or cardiovascular disease (CVD), moderate-severe chronic kidney disease, and fracture was associated with a faster onset of lung disease progression, while a history of gastroesophageal reflux was protective. History of CVA/CVD, diabetes mellitus, and lymphoma were associated with a faster onset of lung transplant/death. Both CCI and RDCI were associated with shorter time to lung disease progression and lung transplant/death in unadjusted analyses. However, only CCI was associated with shorter time to lung transplant/death in analyses adjusted for age, sex, pulmonary function, and radiographic pattern of lung lesion. Conclusions: CCI and RDCI may be useful tools in assessing prognosis in patients with IPAF in terms of both lung disease progression and mortality. Prospective studies are needed to further evaluate the performance of CCI and RDCI and the impact of optimizing comorbid conditions that may mitigate poor outcomes among patients with IPAF.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2025 (prima pubblicazione 2025-02-04).
Identificativi: PMID 39903746 · PMCID PMC11793734 · DOI 10.1371/journal.pone.0316762.
Descrittori MeSH principali: Lung Diseases, Interstitial; Autoimmune Diseases.
Pagina: https://europepmc.org/article/MED/39903746 — https://doi.org/10.1371/journal.pone.0316762. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-06T12:00:49.376Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.